Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R)

被引：29

作者：

Beebe, Xenia ^{[1
]}

Darczak, Daria ^{[1
]}

Davis-Taber, Rachel A. ^{[1
]}

Uchic, Marie E. ^{[1
]}

Scott, Victoria E. ^{[1
]}

Jarvis, Michael F. ^{[1
]}

Stewart, Andrew O. ^{[1
]}

机构：

[1] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 06期

关键词：

PACAP; class B GPCR; PAC(1)-R; hydrazides;

D O I：

10.1016/j.bmcl.2008.01.052

中图分类号：

R914 [药物化学];

学科分类号：

100701 [药物化学];

摘要：

Potent small molecule antagonists for the PAC(1)-R have been discovered. Previously known antagonists for the PAC(1)-R were slightly truncated peptide ligands. The hydrazides reported here are the first small molecule antagonists ever reported for this class B GPCR. (C) 2008 Elsevier Ltd. All rights reserved.

引用

收藏

页码：2162 / 2166

页数：5

相关论文

共 15 条

[1]

VIP and PACAP: very important in pain? [J].

Dickinson, T ;

Fleetwood-Walker, SM .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) :324-329

[2]

Mechanisms of peptide and nonpeptide ligand binding to class B G-protein coupled receptors [J].

Hoare, SRJ .

DRUG DISCOVERY TODAY, 2005, 10 (06) :417-427

[3]

The 7TM G-protein-coupled receptor target family [J].

Jacoby, Edgar ;

Bouhelal, Rochdi ;

Gerspacher, Marc ;

Seuwen, Klaus .

CHEMMEDCHEM, 2006, 1 (08) :760-782

[4]

GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects [J].

Klabunde, T ;

Evers, A .

CHEMBIOCHEM, 2005, 6 (05) :876-889

[5]

Human glucagon receptor antagonists based on alkylidene hydrazides [J].

Ling, A ;

Plewe, M ;

Gonzalez, J ;

Madsen, P ;

Sams, CK ;

Lau, J ;

Gregor, V ;

Murphy, D ;

Teston, K ;

Kuki, A ;

Shi, S ;

Truesdale, L ;

Kiel, D ;

May, J ;

Lakis, J ;

Anderes, K ;

Iatsimirskaia, E ;

Sidelmann, UG ;

Knudsen, LB ;

Brand, CL ;

Polinsky, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (04) :663-666

[6]

Identification of alkylidene hydrazides as glucagon receptor antagonists [J].

Ling, A ;

Hong, YF ;

Gonzalez, J ;

Gregor, V ;

Polinsky, A ;

Kuki, A ;

Shi, SH ;

Teston, K ;

Murphy, D ;

Porter, J ;

Kiel, D ;

Lakis, J ;

Anderes, K ;

May, J .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (19) :3141-3149

[7]

Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist [J].

Moro, O ;

Lerner, EA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) :966-970

[8]

Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist [J].

Moro, O ;

Wakita, K ;

Ohnuma, M ;

Denda, S ;

Lerner, EA ;

Tajima, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) :23103-23110

[9]

Pisegna Joseph R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P58, DOI 10.1097/MED.0b013e328012d605

[10]

Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor - Evidence for dual coupling to adenylate cyclase and phospholipase C [J].

Pisegna, JR ;

Wank, SA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (29) :17267-17274